EDITOR,-We noted with interest the paper by Kubben et al (Gut 1994; 35: 530-5) on a comparison between proliferating cell nuclear antigen (PCNA) and ex vivo bromodeoxyuridine (BrdU) labelling. We have compared PCNA labelling in 86 human colorectal tumours to iododeoxyuridine (IudR) labelling after in vivo administration using both flow cytometric and immunohistochemical methods. '1 In contrast with the authors' findings, we have not found a significant correlation between the two labels. This was despite correcting for the presence of IudR labelled daughter nuclei (a problem that has not been discussed in this paper) and using a variety of fixatives when assessing PCNA labelling. In our experience, the strongest correlation seen has been on comparison between IudR labelling assessed immunohistochemically and PCNA labelling after fixation in methanol (r=0-38, p=0-015). Fixation methods seem to affect the identification of PCNA in different parts of the cell cycle2 and the apparently higher expression of PCNA than BrdU in Kubben's paper reflects this. 
